CLAIMS

1. A compound of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

R^2 is  ;

each R^3 is independently selected from halogen and methyl;

R^5 is a 4 to 9 membered heterocycle containing 1 to 3 heteroatoms selected from the group consisting of N, O and S, wherein the heterocycle is substituted by R^6, and wherein the heterocycle may be optionally substituted with 1 or 2 groups independently selected from methyl, ethyl, isopropyl, *tert*-butyl, difluoromethyl, trifluoromethyl, methoxymethyl, ethynyl, cyclopropyl, and cyclobutyl;

R^6 is selected from the group consisting of 1-prop-2-en-1-one, 1-(2-fluoroprop-2-en-1-one), 1-(2-methylprop-2-en-1-one), and 1-but-2-yn-1-one;

n is 1 or 2.

2. The compound of Claim 1, wherein R^5 is a 6 membered monocyclic heterocycle containing 1 or 2 nitrogen heteroatoms, wherein the heterocycle is attached via a ring nitrogen atom, wherein the heterocycle is substituted by R^6, and wherein the heterocycle may be optionally substituted with 1 or 2 methyl groups.

3. The compound of Claims 1 or 2, wherein R^6 is 1-prop-2-en-1-one.

4. The compound of Claim 1, wherein the compound is selected from:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,
and

,
or a pharmaceutically acceptable salt thereof.

5. The compound:



or a pharmaceutically acceptable salt thereof.

6. The compound:


.

7. A pharmaceutical composition comprising a compound of any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.

8. Use of a compound of any one of Claims 1 to 6, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer.

9. The use of Claim 8, wherein the medicament is to be conjointly administered with at least one additional anti-cancer therapeutic agent.

10. The use of Claim 9, wherein the additional anti-cancer therapeutic agent is selected from the group consisting of trastuzumab, pertuzumab, margetuximab, t-dm1, sacituzumab govitecan-hziy, neratinib, lapatinib, tucatinib, palbociclib, ribociclib, abemaciclib, everolimus, alpelisib, olaparib, talazoparib, cyclophosphamide, methotrexate, 5-fluorouracil, vinorelbine, doxorubicin, paclitaxel, docetaxel, bleomycin, vinblastine, dacarbazine, mustine, vincristine, procarbazine, prednisolone, etoposide, cisplatin, carboplatin, epirubicin, capecitabine, folinic acid and oxaliplatin, cemiplimab, nivolumab, pembrolizumab, avelumab, durvalumab, atezolizumab, aminoglutethimide, testolactone, anastrozole, letrozole, exemestane, vorozole, formetsane, fadrozole, ATD, 6-OXO, fulvestrant, sunitinib, sorafenib, bevacizumab, and pharmaceutically acceptable salts thereof, and combinations thereof.